Home Biosimilar Antibodies Immunology & Inflammation CD markers Vadastuximab (Anti-Siglec-3 / CD33)
For research use only. Not for use in humans.

Vadastuximab (Anti-Siglec-3 / CD33)

Synonyms: Siglec-3， gp67

Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD.

Vadastuximab (Anti-Siglec-3 / CD33)

Quality Control

Batch: A235701 Purity: 99% Protein concentration: 3.51 mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD.

Product Details

CAS No. 1436390-64-5
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07026942 NOT_YET_RECRUITING Relapsed/Refractory AML Nationwide Children's Hospital 2026-04-01 PHASE1; PHASE2
NCT07676006 NOT_YET_RECRUITING Relapsed/Refractory Acute Myeloid Leukemia (AML) Grit Biotechnology 2026-07-01 EARLY_PHASE1
NCT05995041 NOT_YET_RECRUITING Acute Myeloid Leukemia Shenzhen Geno-Immune Medical Institute 2027-06-30 PHASE1
NCT03971799 ACTIVE_NOT_RECRUITING Acute Myelogenous Leukemia Center for International Blood and Marrow Transplant Research 2020-01-08 PHASE1; PHASE2
NCT05945849 RECRUITING Leukemia, Myeloid, Acute University of Pennsylvania 2024-02-23 PHASE1
NCT05662904 NOT_YET_RECRUITING Drug: Gemtuzumab Ozogamicin Relapsed/Refractory Acute Myeloid Leukemia (AML) German Cancer Research Center 2028-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-11-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.